Richard M Goldberg

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. ncbi request reprint Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer
    Richard M Goldberg
    Division of Hematology Oncology, The University of North Carolina at Chapel Hill, CB 7305, 3009 Old Clinic Building, Chapel Hill, NC 27599 7305, USA
    Cancer Chemother Pharmacol 54:S57-64. 2004
  2. ncbi request reprint Advances in the treatment of metastatic colorectal cancer
    Richard M Goldberg
    University of North Carolina at Chapel Hill, 3009 Old Clinic Building, Chapel Hill, North Carolina 27599, USA
    Oncologist 10:40-8. 2005
  3. ncbi request reprint Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial
    Richard M Goldberg
    Division of Hematology and Oncology, University of North Carolina at Chapel Hill, CB 7305, 3009 Old Clinic Bldg, Chapel Hill, NC 27514, USA
    J Clin Oncol 24:3347-53. 2006
  4. ncbi request reprint Current approaches to first-line treatment of advanced colorectal cancer
    Richard M Goldberg
    Division of Hematolgy Oncology, University of North Carolina at Chapel Hill, 27599 7305, USA
    Clin Colorectal Cancer 4:S9-15. 2004
  5. ncbi request reprint Therapy for metastatic colorectal cancer
    Richard M Goldberg
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Oncologist 11:981-7. 2006
  6. ncbi request reprint A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
    Richard M Goldberg
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, CB 7305, 3009 Old Clinic Building, Chapel Hill, NC 27599 7305, USA
    J Clin Oncol 22:23-30. 2004
  7. pmc NCCTG Study N9741: leveraging learning from an NCI Cooperative Group phase III trial
    Richard M Goldberg
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, CB 7305, 170 Manning Drive, Chapel Hill, North Carolina 27599, USA
    Oncologist 14:970-8. 2009
  8. pmc Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics
    Richard M Goldberg
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina27599, USA
    Trans Am Clin Climatol Assoc 121:21-32; discussion 32-3. 2010
  9. pmc Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741
    Howard L McLeod
    University of North Carolina Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC 27599 7360, USA
    J Clin Oncol 28:3227-33. 2010
  10. pmc Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741
    Hanna K Sanoff
    Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7305, USA
    J Clin Oncol 26:5721-7. 2008

Research Grants

Detail Information

Publications93

  1. ncbi request reprint Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer
    Richard M Goldberg
    Division of Hematology Oncology, The University of North Carolina at Chapel Hill, CB 7305, 3009 Old Clinic Building, Chapel Hill, NC 27599 7305, USA
    Cancer Chemother Pharmacol 54:S57-64. 2004
    ..In this paper selected phase III studies from around the globe that tested these new chemotherapy options and led to new standards of care and better expectations for patients with advanced colorectal cancer are reviewed...
  2. ncbi request reprint Advances in the treatment of metastatic colorectal cancer
    Richard M Goldberg
    University of North Carolina at Chapel Hill, 3009 Old Clinic Building, Chapel Hill, North Carolina 27599, USA
    Oncologist 10:40-8. 2005
    ..Ongoing investigations will identify a place for capecitabine, epidermal growth factor inhibitors, and new cytotoxics in the treatment of metastatic CRC...
  3. ncbi request reprint Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial
    Richard M Goldberg
    Division of Hematology and Oncology, University of North Carolina at Chapel Hill, CB 7305, 3009 Old Clinic Bldg, Chapel Hill, NC 27514, USA
    J Clin Oncol 24:3347-53. 2006
    ..High rates of grade > or = 3 toxicity on IFL (resulting in some deaths) led us to reduce the starting doses of both irinotecan and FU by 20% (rIFL). This article compares rIFL with FOLFOX4...
  4. ncbi request reprint Current approaches to first-line treatment of advanced colorectal cancer
    Richard M Goldberg
    Division of Hematolgy Oncology, University of North Carolina at Chapel Hill, 27599 7305, USA
    Clin Colorectal Cancer 4:S9-15. 2004
    ..The history and development of 5-FU-based treatment regimens that include the newer drugs irinotecan, oxaliplatin, and bevacizumab are discussed in light of the impact these advances have made in the treatment of colorectal cancer..
  5. ncbi request reprint Therapy for metastatic colorectal cancer
    Richard M Goldberg
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
    Oncologist 11:981-7. 2006
    ..However, the optimum sequencing of chemo- and biological therapies remains to be established, as does the potential contribution of numerous agents in development...
  6. ncbi request reprint A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer
    Richard M Goldberg
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, CB 7305, 3009 Old Clinic Building, Chapel Hill, NC 27599 7305, USA
    J Clin Oncol 22:23-30. 2004
    ..In this study, we compared the activity and toxicity of three different two-drug combinations in patients with metastatic colorectal cancer who had not been treated previously for advanced disease...
  7. pmc NCCTG Study N9741: leveraging learning from an NCI Cooperative Group phase III trial
    Richard M Goldberg
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, CB 7305, 170 Manning Drive, Chapel Hill, North Carolina 27599, USA
    Oncologist 14:970-8. 2009
    ..To date nearly 30 papers and an even larger number of abstracts have been based upon data arising from the study. The history of the trial and the major findings are summarized in this review...
  8. pmc Leveraging learning from a phase III colorectal cancer clinical trial: outcomes, methodology, meta-analysis and pharmacogenetics
    Richard M Goldberg
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina27599, USA
    Trans Am Clin Climatol Assoc 121:21-32; discussion 32-3. 2010
    ..This review highlights some of those observations. Initiated in 1997, the trial has spawned 26 published or in press papers and 39 abstracts...
  9. pmc Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741
    Howard L McLeod
    University of North Carolina Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC 27599 7360, USA
    J Clin Oncol 28:3227-33. 2010
    ..Pharmacogenetics identifies the likelihood of adverse events or response based on variants in genes involved in drug transport, metabolism, and cellular targets...
  10. pmc Five-year data and prognostic factor analysis of oxaliplatin and irinotecan combinations for advanced colorectal cancer: N9741
    Hanna K Sanoff
    Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7305, USA
    J Clin Oncol 26:5721-7. 2008
    ....
  11. doi request reprint A two-cohort phase I study of weekly oxaliplatin and gemcitabine, then oxaliplatin, gemcitabine, and erlotinib during radiotherapy for unresectable pancreatic carcinoma
    Laura Raftery
    Division of Hematology and Oncology, Ohio State University, Columbus, OH, USA
    Am J Clin Oncol 36:250-3. 2013
    ....
  12. ncbi request reprint Adjuvant therapy for colorectal cancer: yesterday, today, and tomorrow
    Anne W Beaven
    Division of Hematology Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599, USA
    Oncology (Williston Park) 20:461-9; discussion 469-70, 473-5. 2006
    ..Finally, a look to the future shows monoclonal antibodies to be an avenue of great promise infighting colorectal cancer...
  13. pmc Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial
    Hanna K Sanoff
    Department of Medicine, Division of Hematology Oncology, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    J Clin Oncol 27:4109-15. 2009
    ..A subgroup analysis of a multisite National Cancer Institute-sponsored trial (N9741) was performed comparing outcomes of black and white patients with metastatic CRC receiving uniform treatment...
  14. ncbi request reprint First-line therapeutic strategies in metastatic colorectal cancer
    Janine M Davies
    Division of Hematology and Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27590, USA
    Oncology (Williston Park) 22:1470-9. 2008
    ....
  15. ncbi request reprint Combining anti-VEGF approaches with oxaliplatin in advanced colorectal cancer
    Shannon K Penland
    The University of North Carolina at Chapel Hill, NC 27599 7305, USA
    Clin Colorectal Cancer 4:S74-80. 2004
    ..Specifically, studies evaluating VEGF-targeted agents in combination with oxaliplatin-containing regimens in CRC are discussed...
  16. ncbi request reprint The role of targeted therapy in the treatment of colorectal cancer
    Richard M Goldberg
    University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Clin Adv Hematol Oncol 4:1-10; quiz 11-2. 2006
    ..Additional targeted agents are also being developed and are showing promise in clinical trials...
  17. pmc A phase I study of bortezomib in combination with standard 5-fluorouracil and external-beam radiation therapy for the treatment of locally advanced or metastatic rectal cancer
    BERT H O'NEIL
    Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill
    Clin Colorectal Cancer 9:119-25. 2010
    ..The purpose of this study was to determine the maximum tolerated dose (MTD) of bortezomib in combination with chemotherapy and radiation...
  18. pmc Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies
    Thomas E Stinchcombe
    Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7305, USA
    J Thorac Oncol 3:521-6. 2008
    ..This trial was designed to determine the maximum tolerated dose and dose limiting toxicities (DLT) of nab-paclitaxel in combination with gemcitabine...
  19. ncbi request reprint Chemotherapy for advanced colorectal cancer: let's not forget how we got here (until we really can)
    BERT H O'NEIL
    UNC Lineberger Comprehensive Cancer Center, 3009 Old Clinic Building, CB 7305, Chapel Hill, NC 27599 7305, USA
    Semin Oncol 32:35-42. 2005
    ..Chemotherapy is likely to remain a central element of the treatment strategy. Our understanding of its current role is discussed in this article...
  20. pmc Translating research into practice: the role of provider-based research networks in the diffusion of an evidence-based colon cancer treatment innovation
    William R Carpenter
    Department of Health Policy and Management, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC 27599 7411, USA
    Med Care 50:737-48. 2012
    ....
  21. ncbi request reprint The continuum of care: a paradigm for the management of metastatic colorectal cancer
    Richard M Goldberg
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Oncologist 12:38-50. 2007
    ....
  22. ncbi request reprint High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history
    BERT H O'NEIL
    University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599, USA
    J Clin Oncol 25:3644-8. 2007
    ....
  23. ncbi request reprint Current strategies in previously untreated advanced colorectal cancer
    Shannon K Penland
    Division of Hematology Oncology, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7305, USA
    Oncology (Williston Park) 18:715-22, 727; discussion 727-9. 2004
    ..Survival in patients with advanced colorectal cancer is on a positive trajectory. The hope that some patients with advanced disease will be long-term survivors (even without surgery) appears to be within the range of possibility...
  24. pmc Comparison of adverse events during 5-fluorouracil versus 5-fluorouracil/oxaliplatin adjuvant chemotherapy for stage III colon cancer: a population-based analysis
    Hanna K Sanoff
    Department of Medicine, Division of Hematology and Oncology, University of Virginia, Charlottesville, Virginia, USA
    Cancer 118:4309-20. 2012
    ..However, the tolerability of this in the general population of patients with colon cancer is uncertain...
  25. doi request reprint Optimal delivery of cytotoxic chemotherapy for colon cancer
    Laura Raftery
    Division of Hematology and Oncology, University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
    Cancer J 16:214-9. 2010
    ....
  26. ncbi request reprint Angiogenesis inhibition in the treatment of colorectal cancer Part 3 of a 3-part series: targeting VEGF--current and future research directions
    Richard M Goldberg
    University of North Carolina, Chapel Hill, Chapel Hill, NC, USA
    Clin Adv Hematol Oncol 3:1-10; quiz 11. 2005
    ..Randomized trials incorporating combination chemotherapy regimens plus both bevacizumab and cetuximab are currently underway, as are preliminary studies withnovel angiogenesis inhibitors...
  27. pmc Nuclear factor κ-light chain-enhancer of activated B cells is activated by radiotherapy and is prognostic for overall survival in patients with rectal cancer treated with preoperative fluorouracil-based chemoradiotheraphy
    BERT H O'NEIL
    Department of Medicine, University of North Carolina, Chapel Hill, NC 27599 7305, USA
    Int J Radiat Oncol Biol Phys 80:705-11. 2011
    ..The present study was designed to evaluate NF-κB activation in patients with rectal cancer undergoing chemoradiotherapy to determine whether NF-κB activity correlates with the outcome in rectal cancer patients...
  28. doi request reprint Treatment of metastatic colorectal cancer
    Janine M Davies
    Drug Development GI Oncology Fellow, Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Semin Oncol 38:552-60. 2011
    ..Additionally, we will discuss the management of resectable and unresectable liver metastases and directed liver therapies...
  29. pmc Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08
    Carmen J Allegra
    University of Florida, Division of Hematology and Oncology, 1600 SW Archer Ave, Rm N 503, Gainesville, FL 32610, USA
    J Clin Oncol 29:11-6. 2011
    ....
  30. doi request reprint Innovations in chemotherapy for metastatic colorectal cancer: an update of recent clinical trials
    BERT H O'NEIL
    Division of Hematology and Oncology, UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina 27599 7305, USA
    Oncologist 13:1074-83. 2008
    ..Recent innovations in chemotherapy for mCRC are reviewed, with a focus on emerging data that may significantly improve both survival and quality of life for patients with CRC in the future...
  31. ncbi request reprint Cetuximab
    Richard M Goldberg
    Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, 27599 7305, USA
    Nat Rev Drug Discov . 2005
    ..In February 2004, it was granted accelerated approval by the US FDA for the treatment of metastatic colorectal cancer on the basis of tumour response rates in Phase II trials...
  32. doi request reprint Chemoradiation therapy in the management of gastrointestinal malignancies
    Autumn J McRee
    Department of Hematology Oncology, University of North Carolina School of Medicine, NC, USA
    Future Oncol 7:409-26. 2011
    ..This article aims to recapitulate the clinical evidence supporting the use of chemoradiotherapy in a variety of gastrointestinal tumor types...
  33. ncbi request reprint New targeted therapies in gastrointestinal cancers
    Sharlene Gill
    Division of Hematology Oncology, The University of North Carolina at Chapel Hill, CB 7305, 3009 Old Clinic Building, Chapel Hill, NC 27599, USA
    Curr Treat Options Oncol 4:393-403. 2003
    ..The results of ongoing and future research efforts will clarify the optimal use and survival benefit of targeted therapies for patients with GI malignancies...
  34. ncbi request reprint Cetuximab in the treatment of colorectal cancer
    Richard M Goldberg
    Division of Hematology Oncology, University of North Carolina, Chapell Hill, NC, USA
    Clin Adv Hematol Oncol 2:1-10; quiz 11-12. 2004
  35. ncbi request reprint Optimal use of the combination of irinotecan and 5-fluorouracil
    Al B Benson
    Division of Hematology Oncology, Department of Medicine, Feinberg School of Medicine of Northwestern University, Chicago, IL 60611, USA
    Semin Oncol 30:68-77. 2003
    ..Future directions include the testing of a complex array of new agents and the incorporation of laboratory predictors of survival and response as a component of clinical trial design...
  36. doi request reprint Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines?
    Jane L Yen-Revollo
    University of North Carolina Schools of Pharmacy and Medicine, Lineberger Comprehensive Cancer Center, Institute for Pharmacogenomics and Individualized Therapy, Chapel Hill, North Carolina 27599 7360, USA
    Clin Cancer Res 14:8-13. 2008
    ....
  37. pmc Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors
    Thomas E Stinchcombe
    Department of Hematology Oncology, Developmental Therapeutics Group Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA
    Cancer Chemother Pharmacol 60:759-66. 2007
    ..The purpose of this study was to determine the maximum tolerated dose (MTD) of ABI-007, on three different schedules in combination with carboplatin...
  38. ncbi request reprint Managing older patients with colorectal cancer
    Hanna Kelly Sanoff
    Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hill, NC 27599, USA
    J Clin Oncol 25:1891-7. 2007
    ..Despite a growing body of data, a great deal of work is still needed to establish optimal strategies to care for patients diagnosed with cancer later in life...
  39. ncbi request reprint Novel chemotherapeutic and targeted agents in metastatic colorectal cancer: the time has arrived
    BERT H O'NEIL
    University of North Carolina, Division of Hematology and Oncology, Chapel Hill, NC 27599 7305, USA
    Expert Opin Investig Drugs 12:1939-49. 2003
    ..These advancements, as well as data on other novel treatment agents that have been studied specifically in patients with colorectal neoplasms, are discussed in detail...
  40. ncbi request reprint Cancer and leukemia group B gastrointestinal cancer committee
    Richard M Goldberg
    University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
    Clin Cancer Res 12:3589s-95s. 2006
    ..Future efforts aim to evolve new standards of care, evaluate new therapies, and answer relevant biological questions in gastrointestinal cancer...
  41. doi request reprint Optimum chemotherapy regimens for neoadjuvant therapy of hepatic colorectal metastases
    Janine M Davies
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7305, USA
    J Surg Oncol 102:946-54. 2010
    ..This review examines approaches to the neoadjuvant management of colorectal liver metastases with systemic therapies...
  42. doi request reprint Optimal management of metastatic colorectal cancer: current status
    Autumn J McRee
    Department of Hematology Oncology, The University of North Carolina School of Medicine, Chapel Hill, NC 27599, USA
    Drugs 71:869-84. 2011
    ....
  43. doi request reprint Institutional profile. UNC Institute for Pharmacogenomics and Individualized Therapy: interdisciplinary research for individual care
    Tejinder K Rakhra-Burris
    UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7361, USA
    Pharmacogenomics 11:13-21. 2010
    ..IPIT Investigators are actively incorporating a pharmacogenomics curriculum into existing teaching programs at all levels...
  44. pmc Assessing the quality of initial consultations regarding adjuvant colon cancer therapy
    Hanna K Sanoff
    1Division of Hematology Oncology, University of North Carolina School of Medicine, Department of Medicine, Chapel Hill, USA
    Clin Colorectal Cancer 9:113-8. 2010
    ..Adequate information exchange (IE) and informed decision making (IDM) between patient and physician are essential, particularly in the elderly...
  45. doi request reprint Sequential versus combination therapy in the treatment of patients with advanced colorectal cancer
    Usman Shah
    Department of Medicine, The Lineberger Comprehensive Cancer Center, The University of North Carolina School of Medicine, Chapel Hill, NC 27599 7295, USA
    Clin Colorectal Cancer 7:315-20. 2008
    ..This approach will be further refined as progress is made in pharmacogenomics and in prognostic and predictive factors in treating patients with metastatic CRC...
  46. ncbi request reprint Systemic therapy for metastatic colorectal cancer: current options, current evidence
    Hanna Kelly
    Division of Hematology and Oncology, University of North Carolina, 3009 Old Clinic Building, CB 7305, Chapel Hill, NC 27599, USA
    J Clin Oncol 23:4553-60. 2005
    ..Sound clinical judgment must continue to guide treatment decisions while we await data regarding the optimal combination and sequence of fluorouracil, irinotecan, oxaliplatin, bevacizumab, and cetuximab...
  47. ncbi request reprint Cetuximab-associated infusion reactions: pathology and management
    Dhavalkumar D Patel
    Division of Hematology and Oncology, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7280, USA
    Oncology (Williston Park) 20:1373-82; discussion 1382, 1392-4, 1397. 2006
    ..For physicians administering cetuximab, familiarity with acute reaction treatment protocols and preparedness to identify and manage symptoms promptly and effectively are most important to minimize potential risks...
  48. doi request reprint A decade of advances in cytotoxic chemotherapy for metastatic colorectal cancer
    Amy S Lucas
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, North Carolina 27599 7305, USA
    Clin Colorectal Cancer 10:238-44. 2011
    ....
  49. ncbi request reprint A systematic review of the use of quality of life measures in colorectal cancer research with attention to outcomes in elderly patients
    Hanna K Sanoff
    Division of Hematology and Oncology, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7305, USA
    Clin Colorectal Cancer 6:700-9. 2007
    ..Our intent was to assess patterns of use of QOL endpoints in colorectal cancer (CRC) treatment research and to summarize current knowledge about how CRC treatment affects elderly patients...
  50. ncbi request reprint UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters
    Janelle M Hoskins
    UNC Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC 27599 7360, USA
    J Natl Cancer Inst 99:1290-5. 2007
    ..The risk of experiencing irinotecan-induced hematologic toxicity for patients with a UGT1A1*28/*28 genotype thus appears to be a function of the dose of irinotecan administered...
  51. ncbi request reprint Expression of nuclear factor-kappaB family proteins in hepatocellular carcinomas
    BERT H O'NEIL
    Department of Medicine, Division of Hematology and Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
    Oncology 72:97-104. 2007
    ..Recent information has implicated IkappaB family members (e.g. Bcl-3) as possible mediators of NF-kappaB activation. Therefore, we examined the expression of all NF-kappaB family members and downstream targets in HCC...
  52. pmc Platinum neurotoxicity pharmacogenetics
    Sarah R McWhinney
    School of Pharmacy, Institute for Pharmacogenomics and Individualized Therapy, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, Campus Box 7360, 3203 Kerr Hall, Chapel Hill, NC 27599 7360, USA
    Mol Cancer Ther 8:10-6. 2009
    ..These data have the potential for broad clinical implications if mechanistic associations lead to the development of toxicity modulators to minimize the noxious sequelae of platinum chemotherapy...
  53. ncbi request reprint A case of oxaliplatin-related posterior reversible encephalopathy syndrome
    Matthew R Skelton
    Division of Hematology and Oncology, University of North Carolina at Chapel Hill, NC 27599 7305, USA
    Clin Colorectal Cancer 6:386-8. 2007
    ..Magnetic resonance imaging of the brain demonstrated hyperintensity in the white matter of the posterior hemispheres consistent with PRES. Herein, we briefly review the PRES syndrome and its management...
  54. pmc Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer
    Richard M Goldberg
    Division of Hematology and Oncology, University of North Carolina at Chapel Hill, Chapel Hill, NC
    Gastrointest Cancer Res 3:S23-7. 2009
    ....
  55. pmc Colorectal cancer treatment in older patients
    Hanna K Sanoff
    Department of Medicine, Division of Hematology Oncology, University of North Carolina at Chapel Hill and Lineberger Comprehensive Cancer Center, Chapel Hill, NC
    Gastrointest Cancer Res 1:248-53. 2007
    ..Much more research is needed to identify optimal strategies for the treatment of less fit older patients with CRC...
  56. doi request reprint Commentary: Disclosure in oncology -- to whom does the truth belong?
    William A Wood
    University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center, Division of Hematology and Oncology, Chapel Hill, NC 27599 7305, USA
    Oncologist 14:77-82. 2009
    ..We provide practical recommendations to the practicing clinician in the U.S. who wishes to approach a request for nondisclosure, and disclosure itself, in a compassionate and respectful way...
  57. ncbi request reprint Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors
    Matthew P Goetz
    Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 21:3761-9. 2003
    ..Additionally, we investigated the effect of CPT-11 on oxaliplatin pharmacokinetics...
  58. pmc Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer
    Christine M Ribic
    Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Toronto
    N Engl J Med 349:247-57. 2003
    ..We investigated the usefulness of microsatellite-instability status as a predictor of the benefit of adjuvant chemotherapy with fluorouracil in stage II and stage III colon cancer...
  59. ncbi request reprint N9741: a phase III study comparing irinotecan to oxaliplatin-containing regimens in advanced colorectal cancer
    Richard M Goldberg
    Mayo Clinic, Rochester, MN, USA
    Clin Colorectal Cancer 2:81. 2002
  60. ncbi request reprint Efficacy and quality-of-life data are related in a phase II trial of oral chemotherapy in previously untreated patients with metastatic colorectal carcinoma
    Timothy J Hobday
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 20:4574-80. 2002
    ..To evaluate quality of life (QOL) and tumor response after administration of an oral chemotherapy regimen in patients with previously untreated metastatic colorectal cancer...
  61. ncbi request reprint Early detection of toxicity and adjustment of ongoing clinical trials: the history and performance of the North Central Cancer Treatment Group's real-time toxicity monitoring program
    Richard M Goldberg
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 20:4591-6. 2002
    ..We believe the methods described present opportunities for improving patient safety in clinical research...
  62. ncbi request reprint Perspectives on the role of sequential or combination chemotherapy for first-line and salvage therapy in advanced colorectal cancer
    Timothy J Hobday
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    Clin Colorectal Cancer 2:161-9. 2002
    ..Herein, we review recent developments in combination and sequential chemotherapy for metastatic colorectal cancer and the implications for the optimal treatment in these patients...
  63. ncbi request reprint A phase IB study of the pharmacokinetics of gemcitabine and pemetrexed, when administered in rapid sequence to patients with advanced solid tumors
    Grace K Dy
    Department of Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, USA
    Cancer Chemother Pharmacol 55:522-30. 2005
    ..The present study was undertaken to evaluate the efficacy, toxicity, and pharmacokinetics of gemcitabine and pemetrexed when pemetrexed is administered immediately after gemcitabine...
  64. ncbi request reprint A phase I study of radiation therapy and twice-weekly gemcitabine and cisplatin in patients with locally advanced pancreatic cancer
    James A Martenson
    Mayo Clinic, Rochester, MN 55905, USA
    Int J Radiat Oncol Biol Phys 55:1305-10. 2003
    ..Gemcitabine's radiosensitizing properties can theoretically be exploited by twice-weekly administration. This study assessed toxicity in patients with pancreatic cancer treated with radiation therapy, gemcitabine, and cisplatin...
  65. ncbi request reprint CPT-11 for bile-duct and gallbladder carcinoma: a phase II North Central Cancer Treatment Group (NCCTG) study
    Steven R Alberts
    Mayo Clinic and Mayo Foundation, Rochester, MN, USA
    Int J Gastrointest Cancer 32:107-14. 2002
    ..These cancers are typically refractory to standard chemotherapy agents. Based on preclinical work showing activity of CPT-11, we performed a phase II trial to assess its activity in patients with bile-duct or gallbladder carcinomas...
  66. ncbi request reprint A phase II trial of docetaxel and CPT-11 in patients with metastatic adenocarcinoma of the esophagus, gastroesophageal junction, and gastric cardia
    Aminah Jatoi
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Int J Gastrointest Cancer 32:115-23. 2002
    ..With the emergence of data to suggest that single agent docetaxel and irinotecan carry antineoplastic effects in this setting, we determined the response rate of these agents when given in combination...
  67. ncbi request reprint Oxaliplatin, fluorouracil, and leucovorin for patients with unresectable liver-only metastases from colorectal cancer: a North Central Cancer Treatment Group phase II study
    Steven R Alberts
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    J Clin Oncol 23:9243-9. 2005
    ..The use of neoadjuvant chemotherapy to improve the likelihood of resection in disease that is not optimally resectable has not been as well studied...
  68. ncbi request reprint Investigation of the prognostic and predictive value of thymidylate synthase, p53, and Ki-67 in patients with locally advanced colon cancer
    Carmen J Allegra
    National Cancer Institute, Bethesda, MD, USA
    J Clin Oncol 20:1735-43. 2002
    ..To evaluate the value of thymidylate synthase (TS), Ki-67, and p53 as prognostic markers in patients with Dukes' B2 and C colon carcinoma...
  69. ncbi request reprint First-line treatment strategies to improve survival in patients with advanced colorectal cancer
    Sharlene Gill
    Division of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Drugs 64:27-44. 2004
    ..Further improvements in the management of advanced disease will continue to be pursued through the ongoing development of multimodality approaches and the incorporation of novel targeted agents with innovative chemotherapy combinations...
  70. ncbi request reprint Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment
    Axel Grothey
    Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 22:1209-14. 2004
    ..However, the importance of the availability of all three active cytotoxic agents, FU-LV, irinotecan, and oxaliplatin, on overall survival (OS) has not yet been evaluated...
  71. ncbi request reprint Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis
    Leonard L Gunderson
    Radiation Oncology Department, Mayo Clinic Cancer Center, Scottsdale, AZ 85259, USA
    J Clin Oncol 22:1785-96. 2004
    ..To determine survival and relapse rates by T and N stage and treatment method in five randomized phase III North American rectal adjuvant studies...
  72. ncbi request reprint Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741
    Thierry Delaunoit
    Department of Oncology, Mayo Clinic, Rochester, Minnesota 55905, USA
    Cancer 101:2170-6. 2004
    ..The complications observed in these arms highlight the importance of aggressive and immediate supportive care in the management of digestive toxicity...
  73. ncbi request reprint Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer
    Richard M Goldberg
    Mayo Clinic, Rochester, MN 55905, USA
    J Clin Oncol 24:4085-91. 2006
    ..This analysis compares the safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly (FOLFOX4) in patients age younger than and at least 70 years...
  74. ncbi request reprint 5-Fluorouracil-based chemotherapy for advanced colorectal cancer in elderly patients: a north central cancer treatment group study
    Stacy D'Andre
    University of California, Davis, Sacramento, CA, USA
    Clin Colorectal Cancer 4:325-31. 2005
    ..Age alone should not be used to determine whether older patients are treated, because performance status is predictive of dose intensity, response rate, time to tumor progression, and overall survival...
  75. ncbi request reprint Phase 1 and pharmacokinetic study of intravenous irinotecan in refractory solid tumor patients with hepatic dysfunction
    Larry J Schaaf
    Clinical Treatment Unit, The Ohio State University Comprehensive Cancer Center, 1248 James Cancer Hospital, 300 West 10th Avenue, Columbus, 43210, USA
    Clin Cancer Res 12:3782-91. 2006
    ..To determine the recommended starting doses and pharmacokinetics of irinotecan in cancer patients with impaired liver function treated on a weekly schedule...
  76. ncbi request reprint Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901
    David P Ryan
    Massachusetts General Hospital Cancer Center, Boston MA 02114, USA
    J Clin Oncol 24:2557-62. 2006
    ..This phase I/II study evaluated the addition of weekly oxaliplatin to preoperative continuous infusion fluorouracil (FU) and external-beam radiation therapy (RT) in patients with locally advanced rectal adenocarcinoma...
  77. ncbi request reprint Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer
    Elizabeth A Poplin
    Operations Office, 14980 Omicron Dr, San Antonio, TX 78245 3217, USA
    J Clin Oncol 23:1819-25. 2005
    ....
  78. ncbi request reprint Associations between plasma insulin-like growth factor proteins and C-peptide and quality of life in patients with metastatic colorectal cancer
    Jeffrey A Meyerhardt
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer Epidemiol Biomarkers Prev 14:1402-10. 2005
    ..The insulin-like growth factor (IGF) family of proteins is associated with QOL in noncancer populations. We sought to study whether these proteins are associated with QOL in patients with colorectal cancer...
  79. ncbi request reprint Intensive surveillance after stage II or III colorectal cancer: is it worth it?
    Richard M Goldberg
    J Clin Oncol 24:330-1. 2006
  80. ncbi request reprint Cancer and Leukemia Group B/Southwest Oncology Group trial 80405: a phase III trial of chemotherapy and biologics for patients with untreated advanced colorectal adenocarcinoma
    Alan P Venook
    Cancer and Leukemia Group B, Department of Clinical Medicine, University of California San Francisco, 600 Divisadero Box 1770, San Francisco, CA 94115, USA
    Clin Colorectal Cancer 5:292-4. 2005
  81. ncbi request reprint A review of oxaliplatin and its clinical use in colorectal cancer
    Axel Grothey
    Mayo Clinic, Rochester, MN, USA
    Expert Opin Pharmacother 5:2159-70. 2004
    ....
  82. ncbi request reprint Comparative pharmacokinetic study of continuous venous infusion fluorouracil and oral fluorouracil with eniluracil in patients with advanced solid tumors
    Alex A Adjei
    Mayo Clinic and Foundation, Department of Oncology, Rochester, MN 55905, USA
    J Clin Oncol 20:1683-91. 2002
    ..To compare the pharmacokinetics of continuous venous infusion (CVI) fluorouracil (5-FU) with that of oral eniluracil/5-FU and to describe toxicities and clinical activity of prolonged oral administration of eniluracil/5-FU...
  83. ncbi request reprint Revisiting the Cancer and Leukemia Group B/Southwest Oncology Group 80405 Trial: a phase III trial of chemotherapy and biologic agents for patients with untreated advanced colorectal adenocarcinoma
    Alan P Venook
    Cancer and Leukemia Group B, University of California, San Francisco, CA 94115, USA
    Clin Colorectal Cancer 6:536-8. 2007
  84. ncbi request reprint Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
    Sharlene Gill
    Mayo Clinic and Foundation, Rochester, MN 55905, USA
    J Clin Oncol 22:1797-806. 2004
    ....
  85. doi request reprint Chemotherapy in elderly patients with colorectal cancer
    Claus Henning Köhne
    Klinik für Onkologie Hämatologie, Klinikum Oldenburg, Dr Eden Str 10, 26133 Oldenburg, Germany
    Oncologist 13:390-402. 2008
    ..The management of frail elderly patients and those with a short life expectancy should be focused on palliation, while fit elderly patients can receive aggressive therapy in a similar fashion to younger patients...
  86. doi request reprint Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107
    Axel Grothey
    Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 26:183-9. 2008
    ..As these two superior therapies have differing mechanisms of action, we explored whether the improved survival associated with the superior therapy was dependent on tumor response...
  87. ncbi request reprint Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803
    Leonard B Saltz
    Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10021, USA
    J Clin Oncol 25:3456-61. 2007
    ..We evaluated the efficacy and safety of weekly bolus CPT-11 plus FU plus LV in the treatment of patients with completely resected stage III colon cancer...
  88. ncbi request reprint A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903
    Mitchell C Posner
    University of Chicago, 5841 S Maryland Avenue MC5031, Chicago 60637, IL, USA
    Ann Surg Oncol 15:158-64. 2008
    ....
  89. ncbi request reprint Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130
    James A Martenson
    North Central Cancer Treatment Group, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 22:3277-83. 2004
    ..Some patients with colon cancer have a high risk of local recurrence postoperatively. This trial was undertaken to determine whether radiation therapy added to an adjuvant chemotherapy regimen improves outcome in high-risk patients...
  90. ncbi request reprint Impact of complete response to chemotherapy on overall survival in advanced colorectal cancer: results from Intergroup N9741
    Grace K Dy
    Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA
    J Clin Oncol 25:3469-74. 2007
    ..To evaluate clinical characteristics and survival outcomes among patients with locally advanced or metastatic colorectal cancer who achieve a complete response (CR) to systemic treatment either alone or with multimodality approach...
  91. ncbi request reprint Pemetrexed and oxaliplatin for metastatic colorectal cancer: results of a phase I Mayo Cancer Center Research Consortium trial, MC0248
    Steven R Alberts
    Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Clin Colorectal Cancer 6:572-7. 2007
    ..A phase I trial was performed to establish the maximum tolerated dose (MTD) of pemetrexed and oxaliplatin when B(12) and folate supplementation is used...
  92. ncbi request reprint Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer
    Amanda C Ashley
    Division of Medical Oncology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota, USA
    Cancer 110:670-7. 2007
    ..Efficacy and toxicity of oxaliplatin (Eloxatin; Sanofi-Aventis, Paris, France) combined with irinotecan (IROX) were examined in 383 patients enrolled on the IROX arm of Intergroup Study N9741...
  93. ncbi request reprint Cost-effectiveness projections of oxaliplatin and infusional fluorouracil versus irinotecan and bolus fluorouracil in first-line therapy for metastatic colorectal carcinoma
    Bruce E Hillner
    Department of Internal Medicine and Massey Cancer Center, Virginia Commonwealth University, Richmond, Virginia 23298, USA
    Cancer 104:1871-84. 2005
    ..The trade-offs between costs and survival for these two regimens have not been explored...

Research Grants3

  1. UNC Oncology Clinical Translational Research Training Program
    Richard Goldberg; Fiscal Year: 2007
    ..An internal advisory committee that includes senior faculty from each of the four components will select and monitor the progress of scholars, while an external advisory committee will review the program annually. ..